Katy Beckermann, MD, PhD, highlights some of the data presented at IKCS 2023, as well as her appreciation for the inclusion of aspects of patient advocacy in each session.
Dr Beckermann begins by observing the early results of the STELLAR-001 study, which were presented by Dr Sumanta Kumar Pal. Although a phase 1B study, its preliminary data show promising results for the novel tyrosine kinase inhibitor zanzalintinib. Dr Beckermann also discusses Dr Bradley McGregor's presentation on extensions of the COSMIC-313 study in non-clear renal cell carcinoma, a subtype for which there currently is an unmet need.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: IKCS 2023: Interpreting New Data in the Treatment of Metastatic Kidney Cancer - Medscape - Nov 29, 2023.
Comments